Table 2.
Univariable Cox regression analysis estimating the influence of FGF 8, FGF 18 and FGFR 4 expression and clinicopathological parameters on overall survival for patients with adenocarcinoma of the esophago-gastric junction.
| All Patients | Neoadjuvantly Treated Patients | Primarily Resected Patients | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Factors | Hazard Ratio | 95% CI | p Value | Hazard Ratio | 95% CI | p Value | Hazard Ratio | 95% CI | p Value |
| FGF 8 (ref.: high) | |||||||||
| low/absent | 0.61 | (0.43–0.87) | 0.006 | 0.43 | (0.27–0.83) | 0.008 | 0.77 | (0.48–1.24) | 0.287 |
| FGF 18 (ref.: low/absent) | |||||||||
| high | 0.66 | (0.45–0.95) | 0.027 | 0.54 | 0.30–0.97 | 0.039 | 0.80 | (0.49–1.29) | 0.363 |
| FGFR 4 (ref.: high) | |||||||||
| low/absent | 0.9 | (0.64–1.27) | 0.562 | 1.05 | 0.61–1.79 | 0.871 | 0.89 | (0.56–1.40) | 0.615 |
| Age (years) | 1.00 | (0.99–1.02) | 0.887 | 0.98 | 0.96–1.01 | 0.217 | 1.01 | (0.98–1.03) | 0.341 |
| Sex (ref. Male) | |||||||||
| female | 0.87 | (0.56–1.35) | 0.529 | 1.27 | 0.62–2.63 | 0.511 | 0.89 | (0.51–1.54) | 0.672 |
| Neoadjuvant treatment (ref.: no) | |||||||||
| yes | 0.81 | (0.57–1.14) | 0.224 | / | / | / | / | / | / |
| (y)pT (ref.: T3) | |||||||||
| 0 | 0.22 | (0.03–1.60) | 0.135 | 0.22 | (0.03–1.64) | 0.139 | / | / | / |
| 1 | 0.17 | (0.02–1.22) | 0.080 | 0.16 | (0.02–1.20) | 0.075 | / | / | / |
| 2 | 0.58 | (0.39–0.86) | 0.008 | 0.63 | (0.33–1.20) | 0.160 | 0.54 | (0.31–0.91) | 0.020 |
| 4 | 2.74 | (1.37–5.50) | 0.005 | 29.63 | (5.72–153.40) | <0.001 | 1.69 | (0.72–3.99) | 0.228 |
| (y)pN (ref.: N3) | |||||||||
| 0 | 0.23 | (0.14–0.39) | <0.001 | 0.32 | 0.15–0.69 | 0.004 | 0.20 | (0.10–0.39) | <0.001 |
| 1 | 0.40 | (0.25–0.64) | <0.001 | 0.51 | 0.24–1.07 | 0.075 | 0.36 | (0.19–0.68) | 0.002 |
| 2 | 0.63 | (0.40–1.00) | 0.049 | 0.81 | 0.38–1.73 | 0.585 | 0.54 | (0.31–0.97) | 0.040 |
| Tumor differentiation (ref.: 3) | |||||||||
| 0 + 1 | 0.44 | (0.18–1.08) | 0.074 | 0.44 | 0.13–1.47 | 0.185 | 0.45 | (0.11–1.87) | 0.273 |
| 2 | 0.57 | (0.39–0.83) | 0.003 | 0.53 | 0.30–0.93 | 0.027 | 0.64 | (0.39–1.06) | 0.080 |
| Mandard regression grade * (ref.: 3 + 4) | |||||||||
| 1 + 2 | / | / | / | 1.40 | 0.49–4.02 | 0.529 | / | / | / |
| 5 | / | / | / | 2.28 | 0.76–6.86 | 0.143 | / | / | / |
| Lymph node ratio (ref.: <0.3) | |||||||||
| ≥0.3 | 1.93 | (1.35–2.77) | <0.001 | 1.62 | 0.91–2.89 | 0.100 | 2.05 | (1.29–3.25) | 0.002 |
| R (ref.: 0) | |||||||||
| 1 | 2.06 | (1.36–3.10) | <0.001 | 3.43 | 1.79–6.56 | <0.001 | 1.51 | (0.88–2.58) | 0.134 |
| UICC Staging (ref.: II + III + IV) | |||||||||
| 0 + I | 0.34 | (0.19–0.63) | <0.001 | 2.91 | 1.14–7.43 | 0.026 | 0.34 | (0.15–0.75) | 0.007° |
| Adjuvant treatment (ref.: no) | |||||||||
| yes | 1.55 | (1.10–2.18) | 0.013 | 1.33 | 0.75–2.38 | 0.330 | 1.58 | (0.99–2.50) | 0.052 |
CI = confidence interval; FGF = fibroblast growth factor; FGFR = fibroblast growth factor receptor; R = resection margin; UICC = Union for International Cancer Control; * 1 = Complete regression; 2 = Presence of rare residual cancer cells; 3 = increase of number of residual cancer cells, but fibrosis still predominant; 4 = residual cancer outgrowing fibrosis; 5 = absence of regressive changes; ° UICC I + II vs. III + IV in primarily resected patients.